NASDAQ:GMAB - Genmab A/S Stock Price, News & Analysis

$20.36
+0.18 (+0.89 %)
(As of 08/22/2019 01:31 AM ET)
Today's Range
$20.26
Now: $20.36
$20.48
50-Day Range N/A
52-Week Range
$12.10
Now: $20.36
$21.45
Volume146,600 shs
Average Volume185,452 shs
Market Capitalization$2.62 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMAB
CUSIPN/A
CIKN/A
Phone45-7020-2728

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees419
Market Cap$2.62 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive GMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.


Genmab A/S (NASDAQ:GMAB) Frequently Asked Questions

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

What price target have analysts set for GMAB?

3 analysts have issued 12 month target prices for Genmab A/S's shares. Their predictions range from $23.00 to $23.00. On average, they anticipate Genmab A/S's stock price to reach $23.00 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for Genmab A/S.

What is the consensus analysts' recommendation for Genmab A/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genmab A/S.

Has Genmab A/S been receiving favorable news coverage?

News headlines about GMAB stock have been trending positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genmab A/S earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Genmab A/S.

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include Thermo Fisher Scientific (TMO), Home Depot (HD), Honeywell International (HON), Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), Verizon Communications (VZ), Amgen (AMGN), CSX (CSX) and Mcdonald's (MCD).

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the folowing people:
  • Dr. Jan G. J. van de Winkel, Co-Founder, Pres & CEO (Age 58)
  • Mr. David A. Eatwell, Exec. VP & CFO (Age 58)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)
  • Mr. Peter Storm Kristensen, Associate Director of Legal & Non-Independent Director (Age 44)
  • Mr. Daniel J. Bruno, VP of Corp. Controller & Non-Independent Director (Age 39)

When did Genmab A/S IPO?

(GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

When does the company's quiet period expire?

Genmab A/S's quiet period expires on Tuesday, August 27th. Genmab A/S had issued 28,500,000 shares in its IPO on July 18th. The total size of the offering was $505,875,000 based on an initial share price of $17.75. During the company's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Parametric Portfolio Associates LLC (0.29%) and Private Capital Group LLC (0.00%).

Which major investors are buying Genmab A/S stock?

GMAB stock was acquired by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC and Private Capital Group LLC.

How do I buy shares of Genmab A/S?

Shares of GMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $20.36.

How big of a company is Genmab A/S?

Genmab A/S has a market capitalization of $2.62 billion. Genmab A/S employs 419 workers across the globe.View Additional Information About Genmab A/S.

What is Genmab A/S's official website?

The official website for Genmab A/S is http://www.genmab.com/.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab A/S (NASDAQ GMAB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel